CLINDAMYCIN PHOSPHATE

Search structure


Trade Names:	CLEOCIN CLEOCIN PHOSPHATE CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER CLEOCIN T CLINDA-DERM CLINDAGEL CLINDAMYCIN PHOSPHATE CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER CLINDESSE CLINDETS EVOCLIN
Synonyms:	Cleocin Cleocin phosphate Cleocin t Clinda-derm Clindagel Clindamycin 2-dihydrogen phosphate Clindamycin phosphate Clindamycin phosphate system suitability Clindesse Clindets Dalacin Dalacin c phos Dalacin t Evoclin NSC-618653 U 28508 U-28,508 U-28508 Zindaclin
Status:	Approved (1972)
Entry Type:	Small molecule
Molecule Category:	Salt Prodrug
UNII:	EH6D7113I8
Parent Compound:	CLINDAMYCIN

Structure


InChI Key	UFUVLHLTWXBHGZ-MGZQPHGTSA-N
Smile	CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)N(C)C1
InChI	InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C18H34ClN2O8PS
Molecular Weight	504.97
AlogP	0.51
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	5.0
Number of Rotational Bond	9.0
Polar Surface Area	148.79
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	31.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Bacterial 70S ribosome inhibitor	PubMed DailyMed Wikipedia Wikipedia

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Vulvovaginitis	3	D014848	ClinicalTrials
Rosacea	2	D012393	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Mixture

Mixture

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Skin and subcutaneous tissue disorders	13.15
General disorders and administration site conditions	12.49
Immune system disorders	11.04
Gastrointestinal disorders	9.69
Injury, poisoning and procedural complications	7.1
Infections and infestations	6.12
Respiratory, thoracic and mediastinal disorders	5.31
Vascular disorders	4.25
Cardiac disorders	3.78
Nervous system disorders	3.66
Investigations	3.48
Musculoskeletal and connective tissue disorders	3.0
Reproductive system and breast disorders	2.58
Blood and lymphatic system disorders	2.44
Renal and urinary disorders	2.16

Cross References

Resources	Reference
ChEMBL	CHEMBL3184512
DrugCentral	3909
EPA CompTox	DTXSID1048677
FDA SRS	EH6D7113I8
PubChem	443385
SureChEMBL	SCHEMBL37148
ZINC	ZINC000004102185

CONTENTS